Balyasny Asset Management’s CONMED CNMD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.78M | Buy |
+106,785
| New | +$4.34M | ﹤0.01% | 1488 |
|
|
2025
Q3 | – | Sell |
-24,623
| Closed | -$1.28M | – | 2985 |
|
|
2025
Q2 | $1.28M | Sell |
24,623
-68,901
| -74% | -$3.78M | ﹤0.01% | 1950 |
|
|
2025
Q1 | $5.65M | Buy |
+93,524
| New | +$6.03M | 0.01% | 1189 |
|
|
2024
Q4 | – | Sell |
-95,450
| Closed | -$6.86M | – | 2814 |
|
|
2024
Q3 | $6.86M | Sell |
95,450
-76,566
| -45% | -$5.4M | 0.01% | 1125 |
|
|
2024
Q2 | $11.9M | Sell |
172,016
-128,831
| -43% | -$9.4M | 0.02% | 805 |
|
|
2024
Q1 | $24.1M | Buy |
300,847
+261,126
| +657% | +$23.3M | 0.04% | 546 |
|
|
2023
Q4 | $4.35M | Sell |
39,721
-41,578
| -51% | -$4.3M | 0.01% | 1165 |
|
|
2023
Q3 | $8.2M | Buy |
+81,299
| New | +$9.34M | 0.02% | 921 |
|
|
2023
Q2 | – | Sell |
-37,099
| Closed | -$3.85M | – | 2340 |
|
|
2023
Q1 | $3.85M | Sell |
37,099
-21,370
| -37% | -$2.07M | 0.01% | 1183 |
|
|
2022
Q4 | $5.18M | Buy |
+58,469
| New | +$4.85M | 0.01% | 1007 |
|
|
2022
Q3 | – | Sell |
-216,495
| Closed | -$20.7M | – | 2898 |
|
|
2022
Q2 | $20.7M | Buy |
216,495
+9,359
| +5% | +$1.12M | 0.07% | 412 |
|
|
2022
Q1 | $30.8M | Buy |
+207,136
| New | +$28.9M | 0.1% | 277 |
|
|
2021
Q4 | – | Sell |
-110,571
| Closed | -$14.5M | – | 2287 |
|
|
2021
Q3 | $14.5M | Buy |
+110,571
| New | +$14.5M | 0.06% | 433 |
|
|
2021
Q2 | – | Sell |
-123,231
| Closed | -$16.1M | – | 2014 |
|
|
2021
Q1 | $16.1M | Buy |
+123,231
| New | +$14.8M | 0.08% | 337 |
|
|
2020
Q4 | – | Sell |
-138,097
| Closed | -$10.9M | – | 1373 |
|
|
2020
Q3 | $10.9M | Sell |
138,097
-65,306
| -32% | -$5.33M | 0.08% | 359 |
|
|
2020
Q2 | $14.6M | Buy |
+203,403
| New | +$14.2M | 0.13% | 241 |
|
|
2019
Q3 | – | Sell |
-57,182
| Closed | -$4.89M | – | 1225 |
|
|
2019
Q2 | $4.89M | Buy |
57,182
+45,464
| +388% | +$3.74M | 0.03% | 615 |
|
|
2019
Q1 | $975K | Buy |
11,718
+5,814
| +98% | +$422K | 0.01% | 1030 |
|
|
2018
Q4 | $379K | Buy |
5,904
+2,036
| +53% | +$139K | ﹤0.01% | 1165 |
|
|
2018
Q3 | $306K | Sell |
3,868
-7,296
| -65% | -$564K | ﹤0.01% | 1501 |
|
|
2018
Q2 | $817K | Sell |
11,164
-2,087
| -16% | -$142K | ﹤0.01% | 1187 |
|
|
2018
Q1 | $839K | Buy |
+13,251
| New | +$791K | ﹤0.01% | 1287 |
|
|
2017
Q3 | – | Sell |
-128,809
| Closed | -$6.56M | – | 1904 |
|
|
2017
Q2 | $6.56M | Sell |
128,809
-164,598
| -56% | -$8.14M | 0.03% | 676 |
|
|
2017
Q1 | $13M | Buy |
+293,407
| New | +$12.6M | 0.06% | 402 |
|
|
2016
Q4 | – | Sell |
-195,001
| Closed | -$7.81M | – | 1360 |
|
|
2016
Q3 | $7.81M | Buy |
195,001
+190,803
| +4,545% | +$8.1M | 0.05% | 436 |
|
|
2016
Q2 | $200K | Buy |
+4,198
| New | +$178K | ﹤0.01% | 1037 |
|
|
2014
Q4 | – | Sell |
-51,553
| Closed | -$1.9M | – | 675 |
|
|
2014
Q3 | $1.9M | Buy |
+51,553
| New | +$2.05M | 0.01% | 612 |
|
|
2014
Q2 | – | Sell |
-69,433
| Closed | -$3.02M | – | 648 |
|
|
2014
Q1 | $3.02M | Buy |
69,433
+56,470
| +436% | +$2.52M | 0.03% | 439 |
|
|
2013
Q4 | $551K | Buy |
+12,963
| New | +$493K | 0.01% | 456 |
|
Other funds holding CNMD
VPM
VCM
CB
Balyasny Asset Management's CNMD Position: Q1 2026 in Review
Balyasny Asset Management opened a new position in CONMED (CNMD) in Q1 2026: 106,785 shares worth $3.78M. The stake represents ﹤0.01% of the portfolio and ranks #1488 among its holdings. This is a return to the name: Balyasny Asset Management previously reported a position in CNMD as recently as Q2 2025.
Balyasny Asset Management first reported a position in CNMD in Q4 2013 and has held it in 29 quarters since. The position peaked at $30.8M in Q1 2022. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.
- Balyasny Asset Management held 106,785 shares of CONMED worth $3.78M as of Q1 2026.
- CONMED was a new Balyasny Asset Management position in Q1 2026.
- CONMED made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1488 holding.
- Balyasny Asset Management first reported a position in CONMED in Q4 2013 and has held it in 29 quarters since.
- Balyasny Asset Management's CONMED position peaked at $30.8M in Q1 2022.
- 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.